Egyptian International Pharmaceutical Investments (CAI:PHAR) Goodwill: E£0 Mil (As of Mar. 2026)


CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
70 GF Score
Price E£88.87
GF Value E£59.75
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Goodwill?

Egyptian International Pharmaceutical Investments CAI:PHAR +0.75% 70 Goodwill is E£0 Mil as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 70/100 and a GF Value™ of E£59.75 (Significantly Overvalued). The stock has 12 warning signs investors should review.

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Egyptian International Pharmaceutical Investments's goodwill for the quarter that ended in Mar. 2026 was E£0 Mil.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Egyptian International Pharmaceutical Investments's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/15372.957
=0.00

Egyptian International Pharmaceutical Investments's Goodwill-to-Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

Goodwill-to-Asset (Q: Mar. 2026 )=Goodwill/Total Assets
=0/18431.886
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Egyptian International Pharmaceutical Investments Goodwill Related Terms


Egyptian International Pharmaceutical Investments Goodwill Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments Goodwill Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CAI:PHAR
70GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Goodwill is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

Frequently Asked Questions Learn more about Goodwill →
What does a Goodwill of E£0 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Goodwill of E£0 Mil as of Mar. 2026. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Goodwill too high?
Egyptian International Pharmaceutical Investments' current Goodwill is E£0 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Goodwill compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Goodwill of E£0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill for a Drug Manufacturers company?
A good Goodwill depends on the Drug Manufacturers industry context. However, Goodwill should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill mean?
A high Goodwill can signal that a stock is expensive relative to its fundamentals. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Goodwill is E£0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.75, compared to a current price of E£88.87 — trading 48.7% above its estimated fair value. The current Goodwill is E£0 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill calculated?
Goodwill is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Goodwill is E£0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£88.87 is trading 48.7% above its estimated GF Value™ of E£59.75. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Goodwill: E£0 Mil
  • GF Value™: E£59.75 vs. price of E£88.87 (48.7% above fair value)
  • GF Score™: 70/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score

Get the complete analysis for CAI:PHAR

Goodwill is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£88.87
Price
E£59.75
GF Value